DELVE HEALTH Announces New Advisory Board

Share Article

DELVE HEALTH, a software technology company focused on Life Science solutions adds a team of industry entrepreneurs to their advisory board.

Delve Health R&D Intelligence for research and literature review

R&D Intelligence for clinical research and faster literature review process

Delve Health, aims to eliminate lead time to starting Clinical Trials, with automation and big data paralytics. From a single interface, we identify related studies, literatures, interventions, investigators, sites or even the competition

DELVE HEALTH corporation today announced the formation of an Advisory Board composed of three thought leaders who together bring years of experience in life sciences patient recruitment, regulatory affairs, clinical operations and software solutions. They will provide strategic counsel to DELVE HEALTH, a Minnesota-based life sciences software platform company, as it develops products to address unmet research needs.

DELVE HEALTH is currently developing novel solutions capturing data across multiple web-sources, helping its users get to data faster by mining, indexing and organizing data from various websites. Researchers, scientists and doctors are always searching journals, publications and clinical trials for disease specific information, trying to identify better treatment options, understanding prior adverse events and learning about new techniques through published documents and clinical trials. All advisory board members have significant experience in helping get drugs and devices to market faster through automated processes and better study design.

"These distinguished advisors bring a wealth of experience in the world of clinical research and software services. Their prior and current involvement and leadership in defining our go-to market strategy and market need offer us invaluable insight," said Wessam Sonbol, president and co-founder of DELVE HEALTH.

The inaugural members of the Advisory Board include:

Mark Summers – CEO, ThreeWire Inc
With over thirty years of experience in the pharmaceutical and medical device industries, Mark is widely recognized as a veteran entrepreneur and thought leader in the area of accelerating clinical trial patient enrollment. As the founder and CEO of ThreeWire, Inc., he has led the company through the development and patenting of its proprietary model for maximizing clinical trial patient enrollment. His clinical trial experience in the industry and at ThreeWire covers a wide range of therapeutic areas and includes patient recruitment for more than 300 study protocols that have screened in excess of 1,000,000 patients in partnership with over 1,500 sites in more than 20 countries.

Prior to founding ThreeWire, Mark held executive positions at two early stage medical device firms where he drove more than $100 million in global growth following completion of extensive clinical trials.

Sew-wah Tay, CEO, Libra Medical
Dr. Tay founded Libra Medical Inc. in January 2007 after 20 years of experience in the medical device industry. Prior to starting Libra Medical, she was Vice-President or Regulatory and Clinical Affairs at American Medical Systems (AMS) where she effectively grew and restructured the departments to meet the needs of AMS’s growing business. She also served as the Vice-president of Regulatory, Quality and Clinical Affairs at Velocimed, Inc. – a startup company in interventional cardiology arena that was acquired by St. Jude Medical. She was also Vice-President of Regulatory Affairs, Clinical and Quality at Survivalink, a company that developed automated external defibrillators, which was acquired by Cardiac Science.

Ethan Rooney, MBA, CCRP Commercial Officer, Remarque
Mr. Rooney is currently the Chief Commerical Officer at Remarque Systems, a clinical trials software provider specializing in Risk Based Monitoring. Mr. Rooney is an accomplished entrepreneur with nearly 20 years experience in clinical trials, in roles spanning clinical trial operations, monitoring, investigator initiated trials, management, sales and marketing. Prior to Remarque, served as the Vice-president of global sales at Merge Clinical, a division of Merge Healthcare, which was recently acquired by IBM for $1billion. Mr. Rooney also co-founded Symbios Clinical, a Minneapolis-based medical device specialty CRO, which sold to Medpace, Inc. for an industry leading multiple.

About DELVE HEALTH® Corporation
DLEVE HEALTH Corporation is a Minnesota-based technology company, which seeks to provide products through proprietary platform technologies by subscription to users who seek to conduct literature reviews, pre-qualify sites/investigators for clinical trials or to gain an insight into the life science industry. To learn more about DELVE HEALTH, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Wessam Sonbol
since: 12/2015
Follow >
Delve Health

Visit website